A phase I trial to assess the safety of 4 ml DNA C (intramuscular [IM]) [HIV DNA vaccine], and the safety and immunogenicity of DNA C followed by NYVAC C (IM) [HIV vaccine] in an open, randomised comparison to NYVAC C alone in healthy volunteers at low risk of human immunodeficiency virus infection.
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs HIV DNA vaccine; HIV vaccine
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms EuroVacc-02
- 20 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 12 Dec 2005 New trial record.